구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | TAS-120 (TAS-120) Institut National de la Santé Et d…·Advanced or Metastatic Solid Tumor 17 trials·t½ 2.3 h |
|---|---|
Overview Program | TAS-120 |
Overview Company | Institut National de la Santé Et de la Recherche Médicale, France |
Overview Modality | CGT |
Overview Target | Advanced or Metastatic Solid Tumor |
Overview Indication | Soft Tissue Sarcoma |
Overview Phase | PHASE_3 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
PK/PD Half-life | 2.3 h |
Toxicology Major finding | Phase 2 study of futibatinib in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplifications.. Aberrant fibroblast growth factor receptor (FGFR)-driven signaling, predominantly arising from FGFR2 amplification, plays a key role in gastric cancer pathogenesis. This open-label, phase 2 study evaluated the efficacy and safety of futibatinib, an irreversible FGFR1-4 inhibit… |
Clinical Safety signal | Phase 2 study of futibatinib in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplifications.. Aberrant fibroblast growth factor receptor (FGFR)-driven signaling, predominantly arising from FGFR2 amplification, plays a key role in gastric cancer pathogenesis. This open-label, phase 2 study evaluated the efficacy and safety of futibatinib, an irreversible FGFR1-4 inhibit… |
Clinical Selected reported efficacy | ORR 47.1% |
Clinical Reported ORR | 47.1% |
Clinical Result source | ClinicalTrials.gov NCT04601857 |
Clinical Program phase | PHASE_3 |
Clinical Trial ref | NCT04601857 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | TAS-120 (TAS-120) Institut National de la Santé Et d…·Advanced or Metastatic Solid Tumor 17 trials·t½ 2.3 h |
|---|---|
Overview Program | TAS-120 |
Overview Company | Institut National de la Santé Et de la Recherche Médicale, France |
Overview Modality | CGT |
Overview Target | Advanced or Metastatic Solid Tumor |
Overview Indication | Soft Tissue Sarcoma |
Overview Phase | PHASE_3 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
PK/PD Half-life | 2.3 h |
Toxicology Major finding | Phase 2 study of futibatinib in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplifications.. Aberrant fibroblast growth factor receptor (FGFR)-driven signaling, predominantly arising from FGFR2 amplification, plays a key role in gastric cancer pathogenesis. This open-label, phase 2 study evaluated the efficacy and safety of futibatinib, an irreversible FGFR1-4 inhibit… |
Clinical Safety signal | Phase 2 study of futibatinib in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplifications.. Aberrant fibroblast growth factor receptor (FGFR)-driven signaling, predominantly arising from FGFR2 amplification, plays a key role in gastric cancer pathogenesis. This open-label, phase 2 study evaluated the efficacy and safety of futibatinib, an irreversible FGFR1-4 inhibit… |
Clinical Selected reported efficacy | ORR 47.1% |
Clinical Reported ORR | 47.1% |
Clinical Result source | ClinicalTrials.gov NCT04601857 |
Clinical Program phase | PHASE_3 |
Clinical Trial ref | NCT04601857 |
추천 비교
추천 비교